MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412143 | Name: Ciamexon

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ciamexon is a biochemical

Chemical Structure

Ciamexon
Ciamexon
CAS#75985-31-8

Theoretical Analysis

MedKoo Cat#: 412143

Name: Ciamexon

CAS#: 75985-31-8

Chemical Formula: C11H13N3O

Exact Mass: 203.1059

Molecular Weight: 203.25

Elemental Analysis: C, 65.01; H, 6.45; N, 20.68; O, 7.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Ciamexon; BM41.332; BM-41.332; BM 41.332
IUPAC/Chemical Name
(+-)-1-((2-Methoxy-6-methyl-3-pyridyl)methyl)-2-aziridinecarbonitrile
InChi Key
KOYMTVWMCXDJNV-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H13N3O/c1-8-3-4-9(11(13-8)15-2)6-14-7-10(14)5-12/h3-4,10H,6-7H2,1-2H3
SMILES Code
N#CC1N(CC2=CC=C(C)N=C2OC)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Ciamexon has showed activity against tumors in clinical trials.

Preparing Stock Solutions

The following data is based on the product molecular weight 203.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Remers WA, Dorr RT. Chemistry and pharmacology of imexon and related cyanoaziridines. Curr Med Chem. 2012;19(33):5745-53. doi: 10.2174/092986712803988802. PMID: 22998528. 2: Isert B, Schulte S, Mengel K, Friedberg KD. Thermolabile hemoglobin formation by 2-cyanaziridine derivatives. Toxicol Lett. 1995 Aug;78(3):189-94. doi: 10.1016/0378-4274(95)03254-i. PMID: 7624889. 3: Krug J, Lampeter EF, Williams AJ, Procaccini E, Cartledge C, Signore A, Beales PE, Pozzilli P. Immunotherapy with ciamexon in the non obese diabetic (NOD) mouse. Horm Metab Res. 1992 Jan;24(1):1-4. doi: 10.1055/s-2007-1003240. PMID: 1612551. 4: Pipeleers-Marichal M, Ling ZD, Teng H, Pipeleers DG. Transplantation of purified islet cells in diabetic rats. III. Immunosuppressive effect of cyclosporin. Diabetes. 1991 Jul;40(7):931-8. doi: 10.2337/diab.40.7.931. PMID: 2060729. 5: Kahaly G. Nonsteroid immunosuppressants in endocrine orbitopathy. Exp Clin Endocrinol. 1991 May;97(2-3):316-9. doi: 10.1055/s-0029-1211085. PMID: 1915649. 6: Baier J, Neumann HA, Ricken O. No inhibition of interferon gamma release in human lymphocytes by Ciamexone. Cancer Immunol Immunother. 1991;32(5):311-4. doi: 10.1007/BF01789049. PMID: 1900217. 7: Kahaly G. Immunsuppressiva bei endokriner Ophthalmopathie. Klinische und experimentelle Untersuchungen mit Ciclosporin und Ciamexon [Immunosuppressive agents in endocrine ophthalmopathy. Clinical and experimental studies using cyclosporin and ciamexone]. Fortschr Med. 1990 Aug 10;108(23):454. German. PMID: 2210582. 8: Giacovazzo M. New findings in cluster headache. Ann Ital Med Int. 1990 Jul- Sep;5(3 Pt 3):303-11. PMID: 2150489. 9: Abend S, Cormier J, Appel MC, Lueprasitsakul W, Alex S, Mordes JP, Usadel KH, Handler ES, Rossini AA, Braverman LE. The effect of ciamexone on lymphocytic thyroiditis and insulin-dependent diabetes mellitus in the BB/Wor rat. Immunopharmacology. 1990 May-Jun;19(3):163-8. doi: 10.1016/0162-3109(90)90065-m. PMID: 2394579. 10: Tingle MD, Park BK. Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites. Br J Clin Pharmacol. 1990 May;29(5):549-56. doi: 10.1111/j.1365-2125.1990.tb03678.x. PMID: 2350531; PMCID: PMC1380154. 11: Baerwald C, Goebel KM, Krause A, Heymanns J. A randomized controlled trial of ciamexon versus placebo in the immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum. 1990 May;33(5):733-8. doi: 10.1002/art.1780330517. PMID: 2189417. 12: Kahaly G, Lieb W, Müller-Forell W, Mainberger M, Beyer J, Vollmar J, Staiger C. Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo- controlled study. Acta Endocrinol (Copenh). 1990 Jan;122(1):13-21. doi: 10.1530/acta.0.1220013. PMID: 2305603. 13: Baerwald C, Goebel KM, Krause A, Heymanns J. Immunmodulierende Basistherapie der rheumatoiden Arthritis mit Ciamexon [Immunomodulating basic therapy of rheumatoid arthritis using ciamexone]. Schweiz Med Wochenschr. 1989 Dec 9;119(49):1769-71. German. PMID: 2533393. 14: Köhler E, Knospe S, Hahn HJ, Roemer KG, Diamantstein T. Ciamexone suppressed anti-islet ADCC of mononuclear cells and serum from type 1 (insulin-dependent) diabetic patients. Exp Clin Endocrinol. 1989 May;93(2-3):143-6. doi: 10.1055/s-0029-1210847. PMID: 2673806. 15: Utech C, Wulle KG, Panitz N, Kiefer H. Treatment of Graves' ophthalmopathy with new immunosuppressive agents. Dev Ophthalmol. 1989;20:94-9. doi: 10.1159/000417925. PMID: 2591632. 16: Hogan M, Beyer J, Stuermer W, Weber P, Schrezenmeier J. Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Results of a pilot study. Arzneimittelforschung. 1988 Aug;38(8):1185-9. PMID: 3058137. 17: Linn T, Volkmann A, Germann H, Woehrle M, Bretzel RG, Bicker U, Federlin K. Ciamexon in the low dose streptozotocin induced diabetes of mice. Diabetes Res. 1987 Nov;6(3):113-7. PMID: 3325216. 18: Bicker U, Wieczorek L. Neue Therapieansätze bei Autoimmunerkrankungen. Ziel: Selektive Beeinflussung der zell- oder antikörpervermittelten Immunität [New therapeutic approaches in autoimmune diseases. The goal: selective modification of cell or antibody-mediated immunity]. Fortschr Med. 1987 Sep 10;105(26):509-12. German. PMID: 3666650. 19: Isert B, Götz G, van der Trenck KT, Friedberg KD. The binding of ciamexone to globin: its demonstration and some accompanying effects in rats. Toxicol Appl Pharmacol. 1987 Mar 15;87(3):490-7. doi: 10.1016/0041-008x(87)90255-9. PMID: 3564022. 20: Linn T, Germann H, Bretzel RG, Helmke K, Bicker U, Federlin K. Different effect of two immunomodulating agents cyclosporin A and ciamexon on the insulin metabolism of cultured mouse islets. Diabetes Res. 1987 Mar;4(3):121-3. PMID: 3038453.